CNBX Pharmaceuticals Inc.

Equities

CNBX

US13764M2098

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 16:33:19 03/07/2024 BST			5-day change	1st Jan Change
0.00714 ^USD	-4.80%		-6.58%	-50.00%

04-16	CNBX Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024	CI
01-12	CNBX Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended November 30, 2023	CI

Cannabics Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended November 30, 2020

January 14, 2021 at 09:03 pm

Cannabics Pharmaceuticals Inc. announced earnings results for the first quarter ended November 30, 2020. For the first quarter, the company announced sales was USD 0 compared to USD 1,754 a year ago. Operating loss was USD 659,732 compared to USD 815,856 a year ago. Net loss was USD 654,767 compared to USD 5.142 million a year ago. Basic loss per share from continuing operations was USD 0.005 compared to USD 0.038 a year ago.

Latest news about CNBX Pharmaceuticals Inc.

CNBX Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024	04-16	CI
CNBX Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended November 30, 2023	01-12	CI
CNBX Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended August 31, 2023	11-30	CI
CNBX Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2023	14/07/23	CI
CNBX Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended February 28, 2023	14/04/23	CI
CNBX Pharmaceuticals Inc. Announces Board Resignations	08/02/23	CI
CNBX Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended November 30, 2022	13/01/23	CI
Shaul Yemal Resigns Position as Director and Board Member Cnbx Pharmaceuticals Inc	29/12/22	CI
CNBX Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended August 31, 2022	30/11/22	CI
CNBX Pharmaceuticals Inc. Auditor Raises 'Going Concern' Doubt	29/11/22	CI
CNBX Pharmaceuticals Inc. acquired unknown stake in TaGeza Biopharmaceuticals Ltd.	07/11/22	CI
CNBX Pharmaceuticals Inc. Announces That the Company Has Filed A New Patent Application Titled " Compositions Comprising Cannabinoids and Methods of Use Thereof in the Treatment of Cancer" Under the Patent Cooperation Treaty	18/10/22	CI
CNBX Pharmaceuticals Inc. Announces Executive Changes	25/07/22	CI
CNBX Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2022	14/07/22	CI
CNBX Pharmaceuticals Inc. Receives Grant of Patent Notice by the Patent Registry, Intellectual Property Department, the Government of the Hong Kong Special Administrative Region	05/05/22	CI
CNBX Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended February 28, 2022	12/04/22	CI
Cannabics Pharmaceuticals Inc. has Changed its Name to CNBX Pharmaceuticals Inc	28/03/22	CI
Cannabics Pharmaceuticals Inc. Enters into Forbearance Agreement with an Institutional Investor	17/02/22	CI
CNBX Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended November 30, 2021	13/01/22	CI
CNBX Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended August 31, 2021	29/11/21	CI
CNBX Pharmaceuticals Inc. Auditor Raises 'Going Concern' Doubt	28/11/21	CI
Cannabics Pharmaceuticals Inc. Appoints Shaul Yemal as an Independent Director and as A Member of the Audit Committee	19/11/21	CI
Cannabics Pharmaceuticals Inc. Appoints Yonina Tova to Board of Advisors	25/10/21	CI
Cannabics Pharmaceuticals Inc. Files 2 Provisional Patents on Compositions and Methods for Treating Cancer	18/10/21	CI
Neuropsychiatry Expert Dr. Ilya Reznik (MD) Joins Cannabics as Head of Psychedelic Inspired Medicine	13/09/21	CI

Chart CNBX Pharmaceuticals Inc.

Duration

Period

More charts

Company Profile

CNBX Pharmaceuticals Inc. is a clinical-stage company specializing in the discovery, development and commercialization of novel cannabinoid-based products and technologies for the treatment of cancer. The Company's lead product candidate is Cannabics SR, an oral capsule developed for the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome (CACS). Its anti-neoplastic drug candidate under development for Colorectal Cancer (CRC) is RCC-33, a therapy being developed primarily in two settings: one to reduce tumor cell activity in CRC patients as a standalone in neoadjuvant treatment or window of opportunity at the time after colonoscopy, prior to cancer staging, and another for patients with refractory to therapy and adjuvant to surgery also at the time after colonoscopy. The Company indents to initiate Phase I/II clinical trials for both candidates: Cannabics SR and RCC-33.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CNBX PHARMACEUTICALS INC.	-50.00%	222K
VERTEX PHARMACEUTICALS INCORPORATED	+15.58%	121B
REGENERON PHARMACEUTICALS, INC.	+16.60%	110B
ARGENX SE	+17.73%	25.93B
BIONTECH SE	-24.33%	19.27B
GENMAB A/S	-19.35%	16.01B
BEIGENE, LTD.	-17.95%	15.66B
WUXI APPTEC CO., LTD.	-48.32%	14.89B
SAREPTA THERAPEUTICS, INC.	+58.78%	14.47B
NEUROCRINE BIOSCIENCES, INC.	+4.91%	13.91B

Bio Therapeutic Drugs